ArticleCureus2026
Renal Dysfunction Across Etiologies of Chronic Liver Disease: A Cross-Sectional Study From a Tertiary Care Center.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic liver disease (CLD) is a rapidly growing public health challenge globally. Kidney complications are a frequent and serious consequence of CLD, significantly increasing the risk of illness and death. Despite this, renal involvement in newly diagnosed or previously untreated CLD remains incompletely understood.
objectiveThis study evaluated baseline renal function in patients with newly diagnosed CLD and examined the association between specific etiologies, particularly metabolic dysfunction-associated steatotic liver disease (MASLD), and patterns of overt or subclinical renal dysfunction.
methodsA cross-sectional observational study was conducted involving 79 adults newly diagnosed with untreated CLD at a tertiary care hospital in India between March 2023 and August 2024. Individuals with known chronic kidney disease, prior treatment for decompensated CLD, or recent exposure to nephrotoxic medications were excluded. Renal function assessment included standard blood tests, 24-hour urine collections, and estimated glomerular filtration rate (GFR) calculations. To evaluate suspected subclinical renal injury, renal biopsy was performed in 40 clinically selected patients with proteinuria, active urinary sediment, reduced GFR, or suspected glomerular disease.
resultsThe cohort was predominantly composed of middle-aged men, with a mean age of 49.26 years. Alcohol-related liver disease was the most common etiology, affecting 39 patients (49.4%), followed by MASLD (14 patients, 17.7%) and viral hepatitis (B and C combined) (10 patients, 12.7%). Despite 71 patients (88.6%) exhibiting normal serum creatinine levels, biopsies (n=40) revealed substantial underlying structural abnormalities. Non-glomerular lesions were identified in 35 (87.5%) of biopsied cases, while IgA nephropathy was the most frequent glomerular pathology, present in 18 (45.0%) biopsied patients. Overall, nine (11.4%) of the cohort had a reduced GFR, defined as <60 mL/min/1.73m². Patients with MASLD demonstrated a significantly higher prevalence of reduced GFR compared to those with alcohol-related disease, i.e., four (28.6%) versus two (5.1%), corresponding to more than a sevenfold increase in the odds of renal dysfunction.
conclusionSubclinical structural renal damage may be common in the early stages of CLD and often precedes detectable changes in routine blood tests. MASLD is associated with a markedly increased risk of reduced GFR compared to other etiologies. Early and concurrent assessment of renal function in patients with newly diagnosed CLD is critical for identifying subclinical impairment and informing timely clinical management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.